Beauty / Personal CareChina
← Sticker Wall
JOURNEY · DETAIL
Fujifilm: Rising from the Ashes of Film Through Skincare and Medical Imaging
Founded: Dai Nippon Celluloid (the predecessor entity), Shigetaka Komori (appointed CEO in 2003, led the strategic transformation) · FUJIFILM Holdings Corporation
JOURNEY
Key Fields
FIELD STAMPSIndustryBeauty / Personal Care
RegionJapan
ScaleGiant
ChannelOther
Origin
In 1934, to break the monopoly of Western companies on the Japanese film market, the Japanese government facilitated the spin-off of the Fuji Photo Film division from Dai Nippon Celluloid. Starting with motion picture film, it grew to challenge Kodak's global market share. However, with the explosion of digital photography around 2000, global demand for color film entered a freefall at a rate of 20% to 30% annually, threatening 60% of the company's revenue. After taking office in 2003, CEO Shigetaka Komori determined that the only way to survive was not to cling to film, but to audit the company's assets and find a 'second curve' based on core technologies—specifically, the underlying film technologies of anti-oxidation, collagen, nano-dispersion, and precision imaging, which could be migrated into cosmetics, medical imaging, and biopharmaceuticals.
Milestones
1934
Founding Turning Point
In 1934, Dai Nippon Celluloid established the Fuji Photo Film factory in Kanagawa. Renamed FUJIFILM Corporation in 1962, it spent decades competing with Kodak, reaching a 33% global market share in color film by 1997, closely trailing Kodak's 50%.
2000
Industry Collapse Failure
In 2000, digital photography triggered a collapse in global color film demand, which began falling at 20% to 30% annually. At the time, 60% of Fujifilm's revenue and over 70% of its profit came from film. Its core profit pool was nearly wiped out within a decade, forcing massive layoffs and plant closures in Japan.
2003
Strategic Pivot Turning Point
In 2003, Shigetaka Komori became CEO and launched the 'VISION75' mid-term plan (preparing for the company's 75th anniversary). He explicitly abandoned the goal of expanding film market share, restructured the imaging division, and systematically audited underlying patents in anti-oxidation, collagen, and nanotechnology, betting on six new sectors including medical life sciences, cosmetics, optical devices, and high-performance materials.
2006
Diversification Gamble Transition
Fujifilm shifted its R&D focus to pharmaceuticals, establishing the medical life sciences division in 2006 and acquiring assets related to Chugai Pharmaceutical. That same year, it launched the ASTALIFT skincare brand, migrating photo anti-fading and collagen anti-oxidation technologies into skincare products. Initially, the move was met with skepticism, as critics viewed a film company entering the cosmetics market as an outsider.
2012
Divergent Paths from Kodak PMF
In January 2012, Kodak filed for bankruptcy protection. By then, despite revenue pressure, Fujifilm had stabilized through diversification: its medical imaging equipment (FCR digital X-ray, endoscopes) ranked in the global top three, ASTALIFT skincare generated tens of billions of yen in annual sales, and the instax instant camera saw an unexpected resurgence in India and among young women, validating the new revenue structure.
2018
Biotech CDMO Expansion Growth
In 2018, Fujifilm acquired Biogen's biologics manufacturing facility in Denmark (approx. $890 million), scaling up CDMO capacity. Leveraging film-based nano-dispersion technology, it entered the vaccine and biologics contract manufacturing market. During the pandemic, it produced raw materials for COVID-19 vaccines like Moderna, making the biopharma CDMO one of its fastest-growing new businesses.
2024
Full Harvest Growth
In fiscal year 2024 (April 2024 to March 2025), Fujifilm achieved record revenue of approximately 2.9609 trillion yen and operating profit of approximately 330 billion yen. The healthcare segment accounted for over 44% of revenue, while the imaging business (instax, etc.) returned to growth. Its market capitalization exceeded 4 trillion yen, while Kodak's market cap has long hovered between $500 million and $1 billion, less than 1% of Fujifilm's.
Turning Points
- In 2003, Shigetaka Komori abandoned the obsession with defending the film business, repositioning the company from an imaging firm to a materials technology company.
- The 2006 launch of ASTALIFT proved that underlying film technologies could be successfully cross-applied to consumer goods.
- In 2012, as Kodak went bankrupt, Fujifilm achieved profitability through medical imaging, marking a definitive divergence in the two companies' histories.
- Starting in 2018, heavy investment in biopharma CDMO services transformed Fujifilm from a medical equipment supplier into a provider of pharmaceutical infrastructure.
Failures & Pitfalls
- After 2000, the collapse of the film business forced tens of thousands of layoffs and the closure of numerous factories, leading to annual losses exceeding 100 billion yen at one point.
- When ASTALIFT launched, Japanese consumers questioned the credibility of a film company making cosmetics; it took over three years to build a premium reputation.
- Around 2015, aggressive acquisitions of pharmaceutical assets like Kyowa Hakko Kirin led to investor skepticism due to integration difficulties and high goodwill, keeping the stock price depressed for a long time.
- Even after the revenue structure transformation, the company repeatedly lowered earnings guidance as some new sector investments had longer-than-expected payback periods, and growth in biopharmaceuticals fell short of analyst expectations.
关键成功要素
- Founder-style cross-industry inquiry: First identify your own irreplaceable technologies (anti-oxidation, collagen, nano-imaging), then find markets that require them.
- Shigetaka Komori's proactive approach: Initiating restructuring in 2003 while the film business still contributed 70% of profits, rather than waiting until cash flow dried up.
- Willingness to endure long cycles and low returns for new businesses: Both medical and skincare sectors took over a decade to contribute significantly to profits.
- The unexpected resurgence of the instax instant camera line, using a consumer-facing cash cow to subsidize the high-stakes bet on biopharma CDMO.
Lessons
- Before a core business collapses, audit which underlying technologies can be migrated to other industries rather than clinging to product categories.
- The key to transformation is the courage to disrupt oneself while the old business is still profitable. Kodak developed the world's first digital camera in 1975 and a photo-sharing network in 2000, but self-sabotaged out of fear of impacting film margins, missing the window for transformation.
- Cross-industry expansion is not random: Anti-aging skincare and medical imaging both rely on the same axes of anti-oxidation, collagen, and imaging technology, keeping the scope of expansion manageable.
- Precision manufacturing and supply chain capabilities from the film era can be repurposed for medical equipment and biopharma CDMO capacity, with internal synergy costs far lower than external acquisition.
Core Data
- FY2024 Revenue：2.9609 trillion yen (based on public data, not independently verified)
- FY2024 Operating Profit：330 billion yen (based on public data, not independently verified)
- Healthcare Segment Revenue Share：Approx. 44% (approx. 1.3 trillion yen) (based on public data, not independently verified)
- Market Cap (Dec 2025)：Approx. 4.5 trillion yen (based on public data, not independently verified)
- Peak Global Color Film Market Share：Approx. 33% (1997, second only to Kodak's 50%) (based on public data, not independently verified)
- Film Business Share of Total Revenue：Approx. 60% in 2000, dropped to less than 5% in 2024 (based on public data, not independently verified)
- Kodak Market Cap Comparison (2024)：Approx. $500 million to $1 billion, less than 1% of Fujifilm's (based on public data, not independently verified)
Competitors / Peers
Its primary benchmark is Kodak: Kodak developed the world's first digital camera in 1975 but refused to mass-produce it, eventually shrinking into a small printing and chemical company after its 2012 bankruptcy. Fujifilm represents the alternative path for traditional tech giants. Among peers, Canon and Konica Minolta followed the precision equipment route, while Lucky Film in China pivoted to rail transit and new energy materials. By 2026, Fujifilm stands in a position where it competes head-to-head with Canon in medical imaging and with companies like Lonza and WuXi Biologics in the global CDMO market.